




RealRate

MEDICINAL PRODUCTS 2022

Navidea Biopharmaceuticals Inc. Rank 49 of 51





RealRate

MEDICINAL PRODUCTS 2022

Navidea Biopharmaceuticals Inc. Rank 49 of 51



The relative strengths and weaknesses of Navidea Biopharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Navidea Biopharmaceuticals Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 25% points. The greatest weakness of Navidea Biopharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is -177%, being 163% points below the market average of -14%.

Input Variable	Value in 1000 USD
Assets, Current	5,383
Assets, Non-Current	355
General and Administrative Expense	7,450
Goodwill	786
Liabilities, Current	5,300
Liabilities, Non-Current	20
Other Assets	0
Other Compr. Net Income	0
Other Expenses	16
Other Liabilities	700
Other Net Income	346
Other Revenues	532
Property, Plant and Equipment, Net	120
Research and Development	5,142

Output Variable	Value in 1000 USD
Liabilities	6,020
Assets	6,645
Expenses	12,608
Revenues	532
Stockholders Equity	625
Net Income	-11,731
Comprehensive Net Income	-11,731
Economic Capital Ratio	-177%